Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology

08-05-2024 | Cholangiocarcinoma | ASO Author Reflections

ASO Author Reflections: Future Perspectives in Surgical Management of Distal Cholangiocarcinoma: Insights from Surgical Margin Status and Recurrence Patterns

Authors: Ryosuke Umino, MD, Satoshi Nara, MD, Takahiro Mizui, MD, PhD, Takeshi Takamoto, MD, PhD, Daisuke Ban, MD, PhD, Minoru Esaki, MD, PhD, Nobuyoshi Hiraoka, MD, PhD, Kazuaki Shimada, MD, PhD

Published in: Annals of Surgical Oncology

Login to get access

Excerpt

Surgical resection is the only potentially curative treatment for distal cholangiocarcinoma (DCC). However, the rate of R0 resection remains suboptimal, and many patients experience postoperative recurrence despite R0 resection. Consequently, the overall survival (OS) of patients with resected DCC remains poor. In pancreatic cancer, R1 resection indicates the presence of residual tumor cells; it also reflects the tumor’s biological aggressiveness. However, the impacts of surgical margin status on survival and recurrence in DCC have been unclear. …
Literature
1.
2.
Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195–203.CrossRefPubMed
3.
Goetze TO, Bechstein WO, Bankstahl US, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC): a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial. BMC Cancer. 2020;20(1):122.CrossRefPubMedPubMedCentral
4.
5.
Khan TM, Verbus EA, Hong H, Ethun CG, Maithel SK, Hernandez JM. Perioperative versus adjuvant chemotherapy in the management of incidentally found gallbladder cancer (OPT-IN). Ann Surg Oncol. 2022;29(1):37–8.CrossRefPubMed
Metadata
Title
ASO Author Reflections: Future Perspectives in Surgical Management of Distal Cholangiocarcinoma: Insights from Surgical Margin Status and Recurrence Patterns
Authors
Ryosuke Umino, MD
Satoshi Nara, MD
Takahiro Mizui, MD, PhD
Takeshi Takamoto, MD, PhD
Daisuke Ban, MD, PhD
Minoru Esaki, MD, PhD
Nobuyoshi Hiraoka, MD, PhD
Kazuaki Shimada, MD, PhD
Publication date
08-05-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15409-3